Global Blood Therapeutics Inc.

Global Blood Therapeutics Inc.

GBT - Insider Information

Get informed when a big investor buys or sells

+ Follow
Market Cap$4.49B
Close$

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
Global Blood Therapeutics Inc.Global Blood Therapeutics Inc.-14.2--276%22.85.6
$79.37

Current Fair Value

15.9% upside

Undervalued by 15.9% based on the discounted cash flow analysis.

Insider Trades

Loading insider trades…

Congress Trades

Loading congress trades…

Share Statistics

Market cap$4.49 Billion
Enterprise Value$4.89 Billion
Earnings per Share$-4.82
Beta0.46
Outstanding Shares65,594,792

Return

Return on Equity-275.75%ROE
Return on Assets-37.50%
Return on Invested Capital-38.26%

Valuation & Multiples

P/E Ratio-14.21P/E Ratio
PEG-76.79PEG
Price to Sales22.83Price to Sales
Price to Book Ratio68.49Price to Book Ratio
Enterprise Value to Revenue20.82
Enterprise Value to EBIT-16.44
Enterprise Value to Net Income-15
Total Debt to Enterprise0.13
Debt to Equity5.56Debt to Equity

Revenue Sources

No data

Institutional Sentiment (Put/Call)

No data available for the latest quarter.

Institutional Ownership

No data available for the latest quarter.

About Global Blood Therapeutics Inc.

CEO: Ted Love

Global Blood Therapeutics Insider Information FAQ

In the latest 13F quarter on Stockcircle, 7 top investors reduced or sold among tracked top investors. Changes are based on reported share counts in their quarterly filings, not day-to-day trading.

Form 4 insider trades are added as new filings are imported. Top investor 13F holdings refresh after each quarterly filing cycle. Politician trade disclosures are added when new reports are published on Stockcircle.